BiotechTube
Noema Pharma

Noema Pharma

Basel, Switzerland· Est.
noemapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $278M

Overview

Noema Pharma is a private, pre-revenue biotech advancing a pipeline of small-molecule therapies targeting central nervous system disorders. Its lead assets, acquired from Roche, are in Phase 2b development for conditions like trigeminal neuralgia and treatment-resistant depression, representing significant unmet needs. The company is backed by experienced life science investors and led by a team with deep CNS and biopharma expertise, positioning it to potentially bring new treatment options to challenging neurological markets.

NeurologyNeuropsychiatry

Technology Platform

Clinical development of in-licensed small molecules targeting mGluR5 and PDE10A pathways for neurological disorders.

Funding History

3
Total raised:$278M
Venture$112M
Series B$112M
Series A$54M

Opportunities

Positive Phase 2b data could unlock significant value, particularly in high-need orphan indications like trigeminal neuralgia, enabling fast-track regulatory pathways.
The company's focus on both niche and broad neurological markets provides a balanced risk-reward profile, with potential for partnership deals on larger indications like treatment-resistant depression.

Risk Factors

High clinical trial failure risk inherent in CNS drug development; negative Phase 2b results would severely impact valuation.
Dependence on future financing rounds in a potentially volatile capital market poses a dilution or funding risk.
Execution risk associated with a virtual operating model reliant on CROs and key personnel.

Competitive Landscape

Noema faces competition from both generic drugs and novel therapies in development for its target indications. In depression, numerous companies are pursuing rapid-acting and treatment-resistant solutions. In orphan neurology, competition is less crowded but includes other biotechs and specialty pharma companies. Differentiation will hinge on demonstrating superior efficacy and tolerability.

More companies in Small Molecule Drugs →More companies in Switzerland →